IVInge Vangenechten

Inge Vangenechten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Inge Vangenechten has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Alain Gadisseur

    Haemostasis Research Unit, Antwerp University Hospital, Edegem, Belgium

    4 shared publications
  • Jan Jacques Michiels

    Blood Coagulation and Vascular Medicine Center, Goodheart Institute & Foundation in Nature Medicine, Rotterdam, The Netherlands

    2 shared publications
  • Jiri Zavrelova

    Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic

    2 shared publications
  • Miroslav Penka

    Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic

    2 shared publications
  • Ondrej Zapletal

    Department of Pediatric Haematology, University Hospital Brno, Brno, Czech Republic

    2 shared publications
  • Petr Smejkal

    Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    Mapping Laboratory Phenotype–Genotype in Von Willebrand Disease: A Belgian National Survey

    by Inge Vangenechten, Sévérine De Bruijn, Christelle Orlando, Philippe Cauchie, Cédric Hermans, Nadine Francotte, Marie-Agnes Azerad, Ingrid Beukinga, Alain Gadisseur

    Von Willebrand Disease (VWD) is a common inherited bleeding disorder, arising from quantitative or qualitative defects in von Willebrand factor (VWF). Its wide phenotypic variability poses challenges for accurate diagnosis and subtype classification. The B-Will Study is a comprehensive analysis of VWD within the Belgian population, focusing on phenotypic and genotypic characteristics. Patients with suspected VWD were identified from historical records. Extensive laboratory phenotyping, including VWF multimer and genetic analysis, was performed in order to establish definitive VWD classification and subtyping. VWD was confirmed in 511 patients, with type 1 as the predominant subtype, followed by type 2 (especially, 2A/IIE and 2M-GPIbM). Laboratory phenotype and multimeric pattern were concordant in 75% of 323 cases. Genetic analysis revealed at least one causal variant in 92.7% of patients, uncovering 126 unique variants (58 novel variants). MLPA detected large gene deletions in cases lacking variants by direct sequencing, raising overall variant detection to 93.4%. Phenotype–genotype concordance reached 66% of the 247 fully characterized patients' subgroup. The B-Will Study significantly enhances understanding of VWD in Belgium, demonstrating that integrated phenotypic and genotypic evaluation improves diagnostic accuracy and subtype classification. The established VWD biobank provides a foundation for longitudinal studies, advanced genetic testing, and international collaboration to optimize VWD management.

  • Open Access

    Analysis of von Willebrand Disease in the “Heart of Europe”

    by Inge Vangenechten, Petr Smejkal, Jiri Zavrelova, Ondrej Zapletal, Alexander Wild, Jan Jacques Michiels, Zwi Berneman, Jan Blatny, Angelika Batorova, Tatiana Prigancova, et al.

    Background von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name “Heart of Europe,” in order to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. Results A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1–3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. Conclusion This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations.


  • Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study

    by Inge Vangenechten, Petr Smejkal, Ondrej Zapletal, Jan Jacques Michiels, Zwi Berneman, Jiri Zavrelova, Jan Blatný, Miroslav Penka, Alain Gadisseur

    Background von Willebrand disease (VWD) is an inherited bleeding disorder caused by a quantitative (type 1 and 3) or qualitative (type 2) defect of von Willebrand factor (VWF). The heterogeneity of laboratory phenotyping makes diagnosing difficult. Objective A cross-sectional, family-based VWD study in a collaboration between University Hospital Brno (Czech Republic) and Antwerp University Hospital (Belgium) to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods A total of 205 patients with suspected VWD were identified from historical records. Complete laboratory analysis was established using all available VWD assays including VWF multimers and genetic analysis. Results Based on the current International Society of Thrombosis and Haemostasis (ISTH) – Scientific and Standardization Committee VWD classification and type 2A sub-division into 2A/IIA, IID, IIC and IIE, the majority was characterized as a type 1 VWD, followed by type 2. Proposed laboratory phenotypes were confirmed by their multimeric pattern within 98% of this cohort. All type 2, 3 and 75% of type 1 VWD patients were confirmed by underlying causative mutations. Forty-six different causal mutations (117 not previously described in the literature) could be identified. Fifty per cent of all cases was represented by eight individual mutations, mainly p.Pro812ArgfsX31. Thirteen patients had a large heterozygous gene alteration. Conclusion Although an extensive panel of tests was used, VWD classification and (sub)typing remains difficult and fluid. This study provides a cross-sectional overview of the VWD population in the Czech Republic and provides important data to the ISTH/European Association for Haemophilia and Allied Disorders VWD mutation database in linking causal mutations with unique VWD (sub)types. It also identifies new, as not previously described in the literature, causal mutations.


  • Open Access

    A comparative analysis of different automated von Willebrand factor glycoprotein Ib‐binding activity assays in well typed von Willebrand disease patients

    by I. Vangenechten, K. Mayger, P. Smejkal, O. Zapletal, J. J. Michiels, G. W. Moore, A. Gadisseur


  • THE AUTOMATED ENDOGENOUS THROMBIN POTENTIAL (ETP) TEST TO REFLECT COAGULATION CHANGES IN PATIENTS WITH CIRRHOSIS OF THE LIVER

    by A.P. Gadisseur, J. Schouten, S. Francque, I. Vangenechten, F. Vertessen, P. Michielsen, M.G. Van der Planken